Erasca price to book ratio ERAS

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 13.9×
5-year median: 1.6×
Against its 5-year history: 92nd; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.7× to 20.5×
Peer median: 10.6×

Erasca's price to book ratio is 13.9× as of Oct 23, 2026.

That is above its 5-year median of 1.6×, higher than on 92% of days in the last 5 years.

Over that time it ranged from 0.7× in Dec 2023 to 20.5× in Apr 2026.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.9×	2.9×	20.5×
2025	2.8×	0.8×	2.9×
2024	1.6×	0.8×	2.0×
2023	0.9×	0.7×	1.5×
2022	1.4×	1.4×	3.2×
2021	3.9×	3.5×	4.9×

Against its peers

Companies in Drug Manufacturers - General nearest Erasca's size, closest first, today.

Company	Price to book ratio
ERASErasca	13.9×
KNSAKiniksa Pharmaceuticals International	9.2×
LGNDLigand Pharmaceuticals	6.3×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
AMRXAmneal Pharmaceuticals	197×
LQDALiquidia	19.6×
OGNOrganon	3.6×
ALKSAlkermes plc.	4.0×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Erasca

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.